Reliance SARS-CoV-2 Assays

One-Step Multiplex RT-PCR

Sensitive
- Established, gold-standard 1-step RT-PCR workflow for reliable detection of viral RNA

Multiplexed
- Proven performance for the detection of multiple viral targets in a single reaction

Compatible
- Validated with most common RT-PCR systems

Convenient
- Includes molecular controls

Introducing two molecular in vitro diagnostic tests from Bio-Rad for the detection of SARS-CoV-2: the Reliance SARS CoV-2 RT-PCR Assay Kit, for the qualitative detection of nucleic acid from SARS-CoV-2, and the Reliance SARS-CoV-2/FluA/FluB RT-PCR Assay Kit, for the detection and differentiation of SARS-CoV-2, influenza A, and influenza B. These kits are authorized for use with clinical samples under an Emergency Use Authorization (EUA) granted by the U.S. Food and Drug Administration (FDA).



These kits include all reagents required to perform an RT-PCR test:

- Independently developed positive and negative molecular controls from Exact Diagnostics
- Oligonucleotide primers and probes, using sequences designed by the U.S. Centers for Disease Control and Prevention (CDC)
- Reliance One-Step Multiplex RT-qPCR Supermix, optimized for sensitive amplification of multiple targets in a single reaction

Both assays target the SARS-CoV-2 nucleocapsid (N) gene, which has higher viral specificity and may have lower mutation risk than the spike protein gene. Variant analysis confirms that these SARS-CoV-2 assays are not affected by current circulating escape variants (UK, South Africa, Brazil, and California variants), as of February 2021.

The streamlined qPCR workflow can be finished in less than two hours*

* Excludes sample extraction time.

Visit bio-rad.com/RelianceCOVIDKits for more information.

BIO-RAD

Features of the Reliance SARS-CoV-2 RT-PCR Assay Kits

Features	Reliance SARS-CoV-2 RT-PCR Assay Kit	Reliance SARS-CoV-2/FluA/FluB RT-PCR Assay Kit
Intended use*	Qualitative detection of nucleic acid from SARS-CoV-2 in specimens	Simultaneous, qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B viral nucleic acid in specimens
Sensitivity (limit of detection)	125–500 copies/ml	SARS-CoV-2: 125–250 copies/ml Influenza A: 501–1,002 copies/ml Influenza B: 862 copies/ml
Targets detected	SARS-CoV-2 nucleocapsid (N) gene (N1 and N2 regions) Human RNaseP (internal control)	SARS-CoV-2: nucleocapsid (N) gene Influenza A: matrix (M1) gene Influenza B: nonstructural 2 (NS2) gene Human RNaseP (internal control)
Instrument compatibility	Bio-Rad CFX Opus 96 Real-Time PCR System Bio-Rad CFX Opus 384 Real-Time PCR System Bio-Rad CFX96 Touch Real-Time PCR System Bio-Rad CFX384 Touch Real-Time PCR System Bio-Rad CFX96 Dx System Applied Biosystems 7500 Fast Real-Time PCR System	Bio-Rad CFX Opus 96 Real-Time PCR System Bio-Rad CFX96 Touch Real-Time PCR System Bio-Rad CFX96 Dx System Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument
Validated sample extraction methods	Thermo Fisher Scientific MagMAX Viral/Pathogen Nucleic Acid Isolation Kit QIAGEN QIAamp Viral RNA Mini Kit	QIAGEN QIAamp Viral RNA Mini Kit
Throughput	Up to 1,524 samples per day on a 384-well platform	Up to 372 samples per day on a 96-well platform

* Refer to product instructions for use (IFU) for additional information.

Ordering Information

Catalog #	Description
12014115	**Reliance SARS CoV-2 RT-PCR Assay Kit**, 200 reactions
12015361	**Reliance SARS CoV-2/FluA/FluB RT-PCR Assay Kit**, 200 reactions

Related Products

Reagents

012010176	**Reliance One-Step Multiplex RT-qPCR Supermix**, 200 x 20 µl reactions, 1 ml
COV000	**Exact Diagnostics SARS-CoV-2 Negative**, 5 x 0.3 ml
COV019	**Exact Diagnostics SARS-CoV-2 Standard**, 5 x 0.3 ml
COVFLU	**Exact Diagnostics SARS-CoV-2, Flu, RSV Run Control Positive**, 5 x 1 ml
COVFLUNEG	**Exact Diagnostics SARS-CoV-2, Flu, RSV Run Control Negative**, 5 x 1 ml

Instruments

12011319	**CFX Opus 96 Real-Time PCR System**, 96-well, 5-color plus FRET, network-connected real-time PCR detection system, includes CFX Opus 96 base unit, cables
12011452	**CFX Opus 384 Real-Time PCR System**, 384-well, 5-color plus FRET, network-connected real-time PCR detection system, includes CFX Opus 384 base unit, cables
1855195	**CFX96 Touch Real-Time PCR System**, modular thermal cycler platform, includes C1000 Touch Thermal Cycler Chassis, CFX96 Optical Reaction Module, cables
1855485	**CFX384 Touch Real-Time PCR System**, modular thermal cycler platform, includes C1000 Touch Thermal Cycler Chassis, CFX384 Optical Reaction Module, cables
1845097-IVD, 1841000-IVD	**CFX96 Dx Real-Time PCR System**, CFX96 Dx optical reaction module and C1000 Dx Thermal Cycler

PCR Plastics

HSP9955*	**Hard-Shell 96-Well PCR Plates**, low profile, thin wall, skirted, white/white, pkg of 50
HSP3805*	**Hard-Shell 384-Well PCR Plates**, low profile, thin wall, skirted, clear/white, pkg of 50
MSB1001	**Microseal 'B' PCR Plate Sealing Film**, adhesive, optical, pkg of 100

* Or equivalent. Refer to the Hard-Shell PCR Plate Brochure (Bio-Rad bulletin 5496) for other 96- and 384-well colored shell/white well PCR plates.

Visit bio-rad.com/RelianceCOVIDKits for more information.

Bio-Rad PCR reagents and analytical instruments are manufactured under an ISO 13485:2016 certified Quality Management System and are quality control tested to ensure consistent product performance you can trust.

- These products have not been FDA cleared or approved but have been authorized for emergency use by the FDA under an EUA
- Reliance SARS CoV-2 RT-PCR Assay has been authorized only for the detection of nucleic acid from SARS-CoV-2, and not for any other viruses or pathogens
- Reliance SARS CoV-2/FluA/FluB RT-PCR Assay has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acids from SARS-CoV-2, influenza A virus, influenza B virus and not for any other viruses or pathogens
- The emergency use of these products is only authorized for the duration of the declaration that circumstances justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3 (b)(1), unless the declaration is terminated, or authorization is revoked sooner

BIO-RAD

Bio-Rad Laboratories, Inc.

Life Science Group

Website *bio-rad.com* ***USA*** *1 800 424 6723* ***Australia*** *61 2 9914 2800* ***Austria*** *00 800 00 24 67 23* ***Belgium*** *00 800 00 24 67 23* ***Brazil*** *4003 0399*
Canada *1 905 364 3435* ***China*** *86 21 6169 8500* ***Czech Republic*** *00 800 00 24 67 23* ***Denmark*** *00 800 00 24 67 23* ***Finland*** *00 800 00 24 67 23*
France *00 800 00 24 67 23* ***Germany*** *00 800 00 24 67 23* ***Hong Kong*** *852 2789 3300* ***Hungary*** *00 800 00 24 67 23* ***India*** *91 124 4029300* ***Israel*** *0 3 9636050*
Italy *00 800 00 24 67 23* ***Japan*** *81 3 6361 7000* ***Korea*** *82 2 3473 4460* ***Luxembourg*** *00 800 00 24 67 23* ***Mexico*** *52 555 488 7670*
The Netherlands *00 800 00 24 67 23* ***New Zealand*** *64 9 415 2280* ***Norway*** *00 800 00 24 67 23* ***Poland*** *00 800 00 24 67 23* ***Portugal*** *00 800 00 24 67 23*
Russian Federation *00 800 00 24 67 23* ***Singapore*** *65 6415 3188* ***South Africa*** *00 800 00 24 67 23* ***Spain*** *00 800 00 24 67 23* ***Sweden*** *00 800 00 24 67 23*
Switzerland *00 800 00 24 67 23* ***Taiwan*** *886 2 2578 7189* ***Thailand*** *66 2 651 8311* ***United Arab Emirates*** *36 1 459 6150* ***United Kingdom*** *00 800 00 24 67 23*

Bulletin 7448 Ver A US/EG *21-0153 0221 Sig 0121*